Re Contract

PRESS RELEASE                                 

               PROTEOSHOP COLLABORATION WITH REGEN THERAPEUTICS                

Proteome Sciences plc ('Proteome Sciences') is pleased to announce a ProteoSHOP
collaboration funded by ReGen Therapeutics plc ('ReGen') for the
characterization of Colostrinin, a proline-rich polypeptide complex derived
from bovine colostrum, which ReGen are developing as a human and veterinary
nutraceutical. ReGen also believes that the peptides within Colostrinin, or
small molecular weight compounds based on them, may have potential as
pharmaceutical agents for the treatment of Alzheimer's and other
neurodegenerative diseases.

Proteome Sciences will apply its ProteoSHOP proteomic technologies to the
biochemical characterization and activity profiling of Colostrinin. This
follows an earlier proteomic study for ReGen undertaken by Proteome Sciences to
compare the expression of proteins from neuronal cells before and after
treatment with Colostrinin.

Financial details of the collaboration were not disclosed.

Commenting on the announcement, Christopher Pearce, Chief Executive of Proteome
Sciences said:

'We are delighted to be collaborating further with ReGen and helping them
identify the bioactive components of Colostrinin. By combining our ProteoSHOP
toolkit with the expertise we have already developed in Alzheimer's and other
neurodegenerative diseases, Proteome Sciences is uniquely positioned to
undertake this project'.

For further information please contact:

Proteome Sciences plc

www.proteomics.com

Christopher Pearce, Chief Executive     Tel: [phone]

                                        Email: [e-mail]

Public Relations for Proteome Sciences

IKON Associates

Adrian Shaw                             Tel: [phone]

                                        Mobile: [phone]

                                        Email: [e-mail]

 

Notes to Editors:

Proteome Sciences plc applies high sensitivity proteomics to identify and
characterise differential protein expression in diseases for diagnostic,
prognostic and therapeutic applications.  It has to date developed sensitive
blood assays for stroke, vCJD, BSE, solid organ transplant rejection and
Alzheimer's disease. The main focus of its research currently addresses
neurological, neurodegenerative, diabetes/obesity, oncology and cardiovascular
conditions.

In addition to its own proprietary biomarkers, Proteome Sciences has developed
ProteoSHOP (Proteome Sciences High Output Proteomics), a toolbox that offers
high sensitivity and high throughput gel and gel-free proprietary technologies
for the identification of potential biomarkers and drug targets.   These
include specialisation in membrane proteins and protein phosphorylation. 

The Company has also developed a range of specialist reagents to improve the
performance and quantitation of protein separation and characterisation with
mass spectrometry, bioinformatics, statistics and pattern recognition. These
include Sensitizer, PST, qPST and TMT.

The process of commercialisation is being actively pursued across the portfolio
of the Company's programmes and technologies and to date licensing deals have
been signed for the commercialisation of tests for Stroke and TSEs.

Proteome Sciences is headquartered in Cobham, Surrey in the UK and has
laboratories at Kings College Hospital, London and in Frankfurt. It employs 40
full time scientists in addition to its corporate and business development
staff. The Company is listed on the Alternative Investment Market.

                                     ENDS